Ascorbic acid supplementation has been investigated as a treatment for demyelinating CMT1A based on success in transgenic animal models overexpressing Pmp22, the genetic cause of CMT1A (Pareyson et al., 2006; Passage et al., 2004). The gene discussed is PMP22; the disease is Charcot-Marie-Tooth disease type 1A.